ALTAVERA Drug Patent Profile
✉ Email this page to a colleague
When do Altavera patents expire, and what generic alternatives are available?
Altavera is a drug marketed by Xiromed and is included in one NDA.
The generic ingredient in ALTAVERA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for ALTAVERA
Recent Clinical Trials for ALTAVERA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, Davis | Phase 4 |
Washington University School of Medicine | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for ALTAVERA
US Patents and Regulatory Information for ALTAVERA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xiromed | ALTAVERA | ethinyl estradiol; levonorgestrel | TABLET;ORAL-28 | 079102-001 | Aug 3, 2010 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |